Comment - Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma [3]

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 4, 1999, Pages 1488-

  Barzon, Luisa ^a   Fallo, Francesco ^a   Sonino, Nicoletta ^a   Daniele, Otello ^a   Boscaro, Marco ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Department of Medical and Surgical Sciences   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOTANE;

ADRENAL CORTEX CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG INDUCED DISEASE; FOLLOW UP; HUMAN; LETTER; LUNG METASTASIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033306926     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.4.1488     Document Type: Letter

References (8)

1. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
2. Treatment of adrenal carcinoma
3. The Cleveland Clinic experience with adrenal cortical carcinoma
4. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy
5. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer
6. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients
7. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients
8. Adrenocortical carcinoma: Experience in 45 patients